Carfilzomib is an anti-cancer tetrapeptide epoxyketone drug and is used for the treatment of multiple myeloma.
| Mechanism of Action | Carfilzomib prevents tumor growth by inhibiting 20S proteasome activity which leads to an accumulation of polyubiquinated proteins, and ultimately, cell cycle arrest or apoptosis. |
| Molecular Formula | C40H57N5O7 |
| Cancer Applications |
Resesarchers developed a method to evaluate anticancer drug carfilzomib's stability under stress conditions and in a pharmaceutical formulation. This study addresses the lack of data on the stability of Carfilzomib, a proteasome-inhibiting anticancer compound. A stability-indicating UHPLC-UV method for analysis of Carfilzomib was developed and validated within the concentrations of 10–250 μg/mL (Sestak et al, 2026).
|
| References |
Pautasso, Chiara, Sara Bringhen, Chiara Cerrato, Valeria Magarotto, and Antonio Palumbo. "The Mechanism of Action, Pharmacokinetics, and Clinical Efficacy of Carfilzomib for the Treatment of Multiple Myeloma." Expert Opinion on Drug Metabolism & Toxicology 9.10 (2013): 1371-379. Sestak V, Roh J, Klepalova L and Kovarikova P (2016) A UHPLC-UV-QTOF study on the stability of Carfilzomib, a novel proteasome inhibitor. J. Pharm. Biomed. Analysis 124:365-373 |